A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX 23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)
Phase of Trial: Phase III
Latest Information Update: 06 Feb 2019
At a glance
- Drugs V 114 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms PNEU-WAY
- Sponsors Merck Sharp & Dohme
- 28 Jan 2019 Planned End Date changed from 13 Apr 2020 to 10 Feb 2020.
- 28 Jan 2019 Planned primary completion date changed from 13 Apr 2020 to 10 Feb 2020.
- 12 Jul 2018 Status changed from not yet recruiting to recruiting.